WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / April 2026 / K253962

510(k) cleared

ClearCheck (RADCC V2.7)

Radformation, Inc. · Apr 3, 2026 · K253962

FDA cleared the ClearCheck (RADCC V2.7) from Radformation, Inc. on Apr 3, 2026 under K253962, a traditional 510(k). The device falls under product code IYE, Accelerator, Linear, Medical, regulated at 21 CFR 892.5050 as a Class 2 device. The review panel was Radiology.

FDA logged the submission as received on Dec 11, 2025. The decision came 113 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Radformation, Inc. has 4 other decisions in the tracker over the last 12 months: K262452 (AutoContour (RADAC V6)), K260509 (AutoContour (RADAC V5)), K252988 (ChartCheck (RADCH V1.6)), K252863 (ClearCalc Model RADCA V2.6).

Questions & Answers

What did FDA clear under K253962?

K253962 is the FDA 510(k) for ClearCheck (RADCC V2.7), submitted by Radformation, Inc.. FDA's decision date was Apr 3, 2026, under product code IYE (Accelerator, Linear, Medical).

Who makes the ClearCheck (RADCC V2.7)?

Radformation, Inc., based in New York, NY, is the applicant of record for K253962.

How long did the K253962 review take?

FDA received the submission on Dec 11, 2025 and issued its decision on Apr 3, 2026, 113 days later.

← All decisions in April 2026

Sources